Hanseatic Management Services Inc. lowered its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 80.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,036 shares of the biotechnology company’s stock after selling 8,400 shares during the period. Hanseatic Management Services Inc.’s holdings in bluebird bio were worth $280,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the business. Tocqueville Asset Management L.P. lifted its stake in shares of bluebird bio by 78.0% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock valued at $7,649,000 after acquiring an additional 24,400 shares during the last quarter. Quantitative Investment Management LLC lifted its stake in shares of bluebird bio by 1,193.8% in the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock valued at $11,009,000 after acquiring an additional 96,700 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of bluebird bio in the 2nd quarter valued at about $3,257,000. Winfield Associates Inc. lifted its stake in shares of bluebird bio by 6.1% in the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 162 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of bluebird bio in the 2nd quarter valued at about $5,252,000.
In other news, insider Jeffrey T. Walsh sold 9,900 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $149.58, for a total transaction of $1,480,842.00. Following the transaction, the insider now directly owns 28,798 shares of the company’s stock, valued at approximately $4,307,604.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel Lynch sold 500 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total value of $60,000.00. Following the transaction, the director now directly owns 3,300 shares in the company, valued at $396,000. The disclosure for this sale can be found here. Insiders have sold a total of 193,168 shares of company stock worth $25,558,003 over the last three months. Insiders own 3.90% of the company’s stock.
WARNING: “bluebird bio, Inc. (BLUE) Shares Sold by Hanseatic Management Services Inc.” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/17/bluebird-bio-inc-blue-shares-sold-by-hanseatic-management-services-inc.html.
BLUE has been the topic of a number of research analyst reports. Evercore ISI initiated coverage on bluebird bio in a report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price target on the stock. Maxim Group restated a “buy” rating and set a $170.00 price target (up previously from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Barclays PLC initiated coverage on bluebird bio in a report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 price target on the stock. Wedbush restated an “outperform” rating and set a $135.00 price target (up previously from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Finally, Leerink Swann restated an “outperform” rating and set a $162.00 price target (up previously from $145.00) on shares of bluebird bio in a report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $131.05.
bluebird bio, Inc. (BLUE) traded up $3.25 during mid-day trading on Friday, reaching $160.15. The company had a trading volume of 808,800 shares, compared to its average volume of 842,772. bluebird bio, Inc. has a fifty-two week low of $56.80 and a fifty-two week high of $164.80.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. bluebird bio’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.07) earnings per share. equities analysts anticipate that bluebird bio, Inc. will post -6.68 earnings per share for the current fiscal year.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.